Bleomycin, Epirubicin, Carboplatin (BECA) in the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

REFERENCES

• Dimery W, Hong WK. Overview of combined modality therapies for head and neck cancer. JNCI 1993; 85, 2: 95–111.
   PubMedGoogle Scholar
• Pinto HA, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Chin North Am 1991; 5: 667–686.
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Wawro NV, DeConti RC et al. Effectiveness of high-dose infusion of methotrexate followed by leucovorin in carcinomas of the head and neck. Cancer Res, 1968; 28: 108–109.
   Google Scholar
• Veronesi A, Zagonel V, RineIli U et al. High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J Clin Oncol 1985; 3: 1105-1108.
   Google Scholar
• Urba SG, Forastiere AA. Systemic therapy of head and neck cancer: most effective agents of real promise. Oncology 1989; 3: 79–98.
   PubMedGoogle Scholar
• Pinto HA, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am 1991; 5: 667–686.
   PubMed Web of Science ®Google Scholar
• Vogl SE. Chemotherapy of recurrent and metastatic head and neck cancer. In: Vogl SE, ed, Head and neck can-cer. New York: Churchill Livingstone 1988: 65-77.
   Google Scholar
• Pfister PG, Bajorin D, Motzer R et al. Cisplatin/ 5-fluo-rouracil/leucovorin (PFL): greater toxicity but no response in squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 1994; 120: 89–95.
   Google Scholar
• Al-Sarraf M. Management strategies in head and neck cancer: the role of carboplatin. In: Bunns PA Jr, Canetta R, Ozols RF, Rozencqeig M, eds. Carboplatin (JM-8): current perspectives and future directions. Philadelphia: WB Saunders 1990.
   Google Scholar
• Magee MJ, Howard J, Bosl GJ, et al. Phase II trial of 4-epidoxorubicin in advanced carcinoma of head and neck ori-gin. Cancer Treat Rep 1985; 69: 125–129.
   PubMedGoogle Scholar
• Karpovsky B, Karp D, Vaughan C. A phase II random-ized trial of weekly versus every 3 weeks pidoxorubicin in advanced squamous cell cancer of head and neck. Proc Am Soc Clin Oncol 1987; 6: 514.
   Google Scholar
• Cersosino RJ, Hong WK. Epirubicin: a review of phar-macology, clinical activity and adverse effects of an Adriamycin analogue. J Clin Oncol 1986; 4: 425–439.
   PubMed Web of Science ®Google Scholar
• Paccagnella A, Pappagallo GL, Segati R, Zorat P, et al. Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomized study. Eur J Cancer, 1983; 29 A, 5: 704-708.
   Google Scholar
• Guaraldi M, Martoni A, Rossi AP, et al. Treatment of advanced head and neck tumors with PEV-B regimen: a pilot study. Chemioterapia 1988; 7 (5): 341–4.
   PubMedGoogle Scholar
• Giglio R, Cabalar E, Mickiewicz E, et al. Phase II study of high-dose epirubicin as single agent (HDESA) followed by radiotherapy (RT) in patients with locally advanced head and neck tumor. Proc Ann Meet Am Soc Clin Oncol 1992; 11: A 792.
   Google Scholar
• Junor E, Canney P, Yosef H. Carboplatin and 5-fluo-rouracil in advanced and recurrent squamous carcinoma of head and neck. Clin Oncol (Roy Coll Radiol) 1993; 5 (1): 43–45.
   PubMedGoogle Scholar
• WHO Handbook for reporting results of cancer treat-ment. WHO offset publication N° 48, Geneva: WHO, 1979.
   Google Scholar
• Miller AB, Hoogstratten B, Statquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
   PubMed Web of Science ®Google Scholar
• Kaplan G, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
   Web of Science ®Google Scholar
• Forastiere AA. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol 1994; 21, 5, Suppl 12: 20-27.
   Google Scholar
• Adelstein DJ. The community approch to salvage thera-py for advanced head and neck cancer. Semin Oncol 1994; 21, 4, Suppl 7: 52-57.
   Google Scholar
• Skoog LA, Vokes EE. Chemotherapy, biologics, and chemoprevention as systemic therapies of head and neck can-cer. Curr Opin Oncol 1994; 6: 277–284.
   PubMedGoogle Scholar
• Cappelaere P, Vignond J, Fargeot P, et al. Palliative chemotherapy of epidermoid carcinoma of the upper respira-tory and digestive tracts with combination of carboplatin and 5-fluorouracil. Bull Cancer 1990; 77: 1009-1105.
   Google Scholar
• Eisenberger M, Krasnow S, Ellenberg S, et al. A com-parison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer. J Clin Oncol 1989; 7: 1341–1345.
   PubMed Web of Science ®Google Scholar
• Maipang T, Watanaarepornchai S, Panjapiyakul C, et al. Cisplatinum-epirubicin chemotherapy for advanced unre-sectable squamous cell carcinoma of the head and neck. Head Neck 1993; 15 (2): 109–114.
   PubMed Web of Science ®Google Scholar
• Bachouchi M, Cvitkovic E, Nasser A, et al. High com-plete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. JNCI 1990; 82, 7: 616–620.
   PubMedGoogle Scholar
• Adamo V, Maisano R, Pergolizzi S, Altavilla G, Caristi N, Chiofalo G, Scimone A. Bleomycin, epidoxorubicin, car-boplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of head and neck (SCCHN): A phase II study. Ann Oncol 1994; 5 ( supp1.8): 1994, abst. P598, 119.
   Google Scholar
• Altun M, Fandi A, Dupuis 0, Cvitkovic E, Krajina Z, Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995; 32, 3: 859–877.
   PubMedGoogle Scholar